FiercePharma11h
Astellas shifts investment focus to later-stage opportunities amid reprioritization
Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.
Pharmabiz1d
Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer
Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...
Armed robbery in Revesby1d
Pfizer, Astellas' PADCEV Plus KEYTRUDA Shows Efficacy
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...
Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit
Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...
Pfizer and Astellas report improved survival in bladder cancer trial
NEW YORK & TOKYO - Pfizer Inc. (NYSE: NYSE:PFE) and Astellas Pharma Inc. (TSE: TYO:4503) have announced updated results from the Phase 3 EV-302 clinical trial, which showed that the combination of ...